NFKB1 and COVID-19: IL‐1β is a highly proinflammatory factor that promotes excessive inflammation and CS in COVID‐19 through activation and circulation of the NF‐κB pathway, therefore, blocking IL‐1β may be an effective strategy for COVID‐19 treatment.